Physician profile
Russell E Rider
NPI 1245244649
$1,224.98
in general payments reported to CMS, 2019-2025
12 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $68.95 · 2021: $87.58 · 2022: $197 · 2023: $170 · 2024: $260 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $677.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $217.48 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $98.35 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $62.69 | 2019 | |
| Abbvie INC. | $39.44 | 2022-2025 | |
| Glaxosmithkline, LLC. | $30.85 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Idorsia Pharmaceuticals US INC | $22.80 | 2023 | Quviviq |
| Abbott Laboratories | $22.53 | 2023 | Freestyle Libre 2 |
| Exact Sciences Corporation | $18.86 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $11.92 | 2020 | |
| Pfizer INC. | $11.60 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Rider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.